drugset
drugset / Trial / NCT05541471

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

NCT05541471 ↗

Phase 1 Completed 37 enrolled Vertex Pharmaceuticals Incorporated
NaSequentialOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics of midazolam and digoxin in the absence and presence of VX-548.

Timeline

Start
2022-09-22
Primary completion
2023-04-16
Completion
2023-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified — Oral
Subject Midazolam Small molecule — Oral
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.